Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …

In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …

Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …

The objectives of this study were to assess the immunogenicity and safety of COVID-19
vaccines in patients with hematologic malignancies. A systematic review and meta-analysis …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

This is a multicenter prospective observational study that included a large cohort (n= 397) of
allogeneic (allo‐HSCT;(n= 311) and autologous (ASCT) hematopoietic stem cell transplant …

Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor
T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 …

Hematopoietic cell transplantation (HCT) and cellular therapy (CT) recipients have poor
outcomes after developing COVID-19 (Spanjaart et al., 2021, Meir et al., 2021). HCT and/or …